2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Titel:
2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
Auteur:
Zhou, C. Das Thakur, M. Srivastava, M.K. Zou, W. Xu, H. Ballinger, M. Felip, E. Wakelee, H. Altorki, N.K. Reck, M. Liersch, R. Kryzhanivska, A. Harada, M. Tanaka, H. Hamm, J. McCune, S. McNally, V. Bennett, E. Gitlitz, B. Novello, S.